Organon & Co (OGN)

NYSE
24.23
+0.83(+3.55%)
  • Volume:
    1,371,158
  • Day's Range:
    23.35 - 24.24
  • 52 wk Range:
    23.34 - 39.47
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

OGN Overview

Prev. Close
23.4
Day's Range
23.35-24.24
Revenue
6.37B
Open
23.7
52 wk Range
23.34-39.47
EPS
4.36
Volume
1,371,158
Market Cap
6.15B
Dividend (Yield)
1.12
(4.79%)
Average Vol. (3m)
1,617,547
P/E Ratio
6.56
Beta
0.517
1-Year Change
-29.79%
Shares Outstanding
254,329,853
Next Earnings Date
Nov 10, 2022
What is your sentiment on Organon Co?
or
Vote to see community's results!

Organon & Co News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Organon & Co Analysis

Organon & Co Company Profile

Organon & Co Company Profile

Employees
0

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company’s biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Read More

Analyst Price Target

Average39.43 (+62.73% Upside)
High44
Low35
Price24.23
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • Being a superior digital money worker, I have had the option to make a decent history with Mrs. Pamela Exchange administration, with her day to day flags have made more than $500k in 14days. I might want to prescribe her to beginners and current financial backers to exploit her program. Reach her on "Pamela E " on F. a. c. e. b. o. o. k/ What'sapp ➡️+1(470)567-6125
    0
    • Too early to judge. Just holding for a while.
      0
      • Careful here. Results coming in a couple days.
        0
        • Price is right to buy again.
          0
          • Turning out to be a good move.
            0
            • Div day on 20th. Then what? Hold?
              0
              • dividend day is the 20th. Get it or wait...
                0
                • Buffet Effecf :D
                  0
                  • OGN even pays a decent dividend.
                    0
                    • so if you don't know, a fund wanted to buy some shares below the price of the market (below 29), now see that the shares goes down. Personally i will just hold myself to the sit and keep an eye on the data...
                      0